Cardinal Health Q2 2025 Filing

TL;DR

**CARDINAL HEALTH (CAH) Q2 2025 FILING OUT NOW - CHECK FINANCIALS**

AI Summary

Cardinal Health Inc. reported its second-quarter results for the period ending December 31, 2024. The company's filing indicates a fiscal year end of June 30th. Key financial data and segment information are included in this 10-Q filing.

Why It Matters

This filing provides investors with an update on Cardinal Health's financial performance and operational status for the second quarter of fiscal year 2025.

Risk Assessment

Risk Level: low — This is a routine quarterly filing providing financial updates, not indicating immediate significant risk.

Key Players & Entities

• CARDINAL HEALTH INC (company) — Filer
• 7000 CARDINAL PLACE (location) — Business Address
• DUBLIN (location) — City
• OH (location) — State
• 0630 (date) — Fiscal Year End
• 20241231 (date) — Period of Report
• 20250130 (date) — Filed as of Date

FAQ

Key Financial Figures

• $55.3 billion — ecember 31, 2024 decreased 4 percent to $55.3 billion and $107.5 billion, respectively, from
• $107.5 b — ecreased 4 percent to $55.3 billion and $107.5 billion, respectively, from the comparati
• $549 million — ecember 31, 2024 increased 9 percent to $549 million from the comparative prior-year quarter
• $1.1 billion — hs ended December 31, 2024 increased to $1.1 billion from the comparative prior-year period,
• $585 million — charges related to the GMPD segment of $585 million recognized during the six months ended
• $635 million — erating earnings increased 9 percent to $635 million for the three months ended December 31,
• $1.3 billion — rating earnings increased 10 percent to $1.3 billion for the six months ended December 31, 2
• $1.91 — segment. This had an adverse impact of $1.91 per share to GAAP diluted EPS for the s
• $1.65 — hs ended December 31, 2024 increased to $1.65 and $3.35, respectively, from the compa
• $3 — ecember 31, 2024 increased to $1.65 and $3.35, respectively, from the comparative
• $1.93 — ecember 31, 2024 increased 2 percent to $1.93 and 6 percent to $3.81, respectively, f
• $3.8 billion — Our cash and equivalents balance was $3.8 billion at December 31, 2024 compared to $5.1 b
• $5.1 billion — illion at December 31, 2024 compared to $5.1 billion at June 30, 2024. During the six months
• $2.0 b — t cash used in operating activities was $2.0 billion, which was primarily impacted by
• $692 million — ncludes the impact of payments totaling $692 million related to the opioid litigation. In a

Filing Documents

• cah-20241231.htm (10-Q) — 1548KB
• a25q2_10qx123124xexhibit311.htm (EX-31.1) — 10KB
• a25q2_10qx123124xexhibit312.htm (EX-31.2) — 10KB
• a25q2_10qx123124xexhibit321.htm (EX-32.1) — 6KB
• a25q2_10qx123124xexhibit991.htm (EX-99.1) — 41KB
• cah-20241231_g1.jpg (GRAPHIC) — 29KB
• cah-20241231_g2.jpg (GRAPHIC) — 27KB
• cah-20241231_g3.jpg (GRAPHIC) — 24KB
• cah-20241231_g4.jpg (GRAPHIC) — 23KB
• cah-20241231_g5.jpg (GRAPHIC) — 33KB
• 0000721371-25-000013.txt ( ) — 8511KB
• cah-20241231.xsd (EX-101.SCH) — 50KB
• cah-20241231_cal.xml (EX-101.CAL) — 54KB
• cah-20241231_def.xml (EX-101.DEF) — 334KB
• cah-20241231_lab.xml (EX-101.LAB) — 710KB
• cah-20241231_pre.xml (EX-101.PRE) — 531KB
• cah-20241231_htm.xml (XML) — 1067KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 2 Explanation and Reconciliation of Non-GAAP Financial Measures 15

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 18

Controls and Procedures

Controls and Procedures 18

Legal Proceedings

Legal Proceedings 19

Risk Factors

Risk Factors 19 Unregistered Sales of Equity Securities and Use of Proceeds 20 Financial Statemen ts 21 Exhibits 41 Form 10-Q Cross Reference Index 42

Signatures

Signatures 43 About Cardinal Health Cardinal Health, Inc., an Ohio corporation formed in 1979, is a global healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists, and manufacturers for integrated care coordination. We report our financial results in two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics. As used in this report, "we," "our," "us," and similar pronouns refer to Cardinal Health, Inc. and its majority-owned and consolidated subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2025 and fiscal 2024 and to FY25 and FY24 are to the fiscal years ending or ended June 30, 2025 and June 30, 2024, respectively.

Forward-Looking Statements

Forward-Looking Statements This Quarterly Report on Form 10-Q for the quarter ended December 31, 2024 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates, and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook, and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected, or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 ("2024 Form 10-K"), our Form 10-Q for the quarter ending September 30, 2024, and other SEC filings made since June 30, 2024. Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement. Non-GAAP Financial Measures In the "Overview of Consolidated Results" section of MD&A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the United States Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financi

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations The discussion and analysis presented below is concerned with material changes in financial condition and results of operations, including amounts and certainty of cash flows from operations and from outside sources, between the periods specified in our condensed consolidated balance sheets at December 31, 2024 and June 30, 2024, and in our condensed consolidated statements of earnings and our condensed consolidated statements of cash flows for the three and six months ended December 31, 2024 and 2023. All comparisons presented are with respect to the prior-year period, unless stated otherwise. Our previously reported segment results have been recast to conform to our new reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change. All of the revisions are reflected throughout this Form 10-Q. See Note 1 of the "Notes to Condensed Consolidated Financial Statements" for additional information. The discussion and analysis in this Form 10-Q should be read in conjunction with the MD&A included in our 2024 Form 10-K. 2 Cardinal Health | Q2 Fiscal 2025 Form 10-Q MD&A Overview Overview of Consolidated Results Revenue Revenue for the three and six months ended December 31, 2024 decreased 4 percent to $55.3 billion and $107.5 billion, respectively, from the comparative prior-year periods, primarily due to the expiration of the OptumRx contracts, partially offset by branded and specialty pharmaceutical sales growth from existing and new customers. GAAP and Non-GAAP Operating Earnings Three Months Ended December 31, Six Months Ended December 31, (in millions) 2024 2023 Change 2024 2023 Change GAAP operating earnings $ 549 $ 505 9 % $ 1,117 $ 473 N.M. Restructuring and employee severance 9 28 33 53 Amortization and other acquisition-rela

View Full Filing

View this 10-Q filing on SEC EDGAR